Report #2832443

Received Mar 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

internal between 1st dose and 2nd dose was too long; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (recived 1st dose over a year ago). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: internal between 1st dose and 2nd dose was too long). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 12-MAR-2025 This case was reported by a patient via interactive digital media. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. The patient had a question should he/she get another one 2-6 months from the latest dose.